NFKB1 and plasma cell myeloma: Consequently, NF-κB signaling has emerged as an attractive molecular target for pharmacological intervention and its inhibitors as potential sensitizer to anticancer drugs; however, despite the clinical success in newly diagnosed and relapsed/refractory multiple myeloma (MM) and mantle cell lymphoma patients, the NF-κB inhibitor bortezomib (Valcade) has fallen short of original expectations (Lin et al., 2010; Godwin et al., 2013).